Cue Biopharma (NASDAQ:CUE) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Cue Biopharma (NASDAQ:CUE) from a buy rating to a hold rating in a report published on Saturday.

Separately, Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Cue Biopharma Stock Performance

NASDAQ CUE opened at $27.64 on Friday. The firm has a market capitalization of $116.09 million, a P/E ratio of -1.02 and a beta of 2.47. The stock has a 50-day simple moving average of $29.47 and a two-hundred day simple moving average of $143.72. Cue Biopharma has a fifty-two week low of $4.97 and a fifty-two week high of $45.50.

Cue Biopharma (NASDAQ:CUE) last issued its earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.

Insider Buying and Selling at Cue Biopharma

In other Cue Biopharma news, CEO Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total value of $1,084,000.00. Following the completion of the transaction, the chief executive officer owned 724,253 shares of the company’s stock, valued at approximately $19,627,256.30. The trade was a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 8,829 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $265,664.61. Following the sale, the insider owned 118,545 shares in the company, valued at $3,567,019.05. This trade represents a 6.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 72,715 shares of company stock valued at $2,041,555. Corporate insiders own 14.56% of the company’s stock.

Institutional Trading of Cue Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. increased its holdings in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Cue Biopharma during the third quarter valued at $62,000. Stifel Financial Corp grew its position in shares of Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares in the last quarter. Finally, Boothbay Fund Management LLC raised its position in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the last quarter. 35.04% of the stock is currently owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.